SOARING SOUTH KOREAN MEDICAL DEVICES MARKET
BioSpectrum Asia
|BioSpectrum Asia Sep 2021
The pandemic induced rise in healthcare expenditure has catalysed the growth of the medical devices market. Growing healthcare needs are significantly influencing the development of novel diagnostic and surgical tools. To meet the regional and international demand for medical devices, South Korea is taking all the necessary steps to support the country’s major market players. We shall take a closer look at the big movers and shakers of the industry.
In May 2021, Ministry of Food and Drug Safety (MFDS), government of South Korea reported that for the first time ever, the number of medical devices produced by local companies has surpassed those imported from other countries since 2011. The number of local companies’ medical devices reported to the government in 2020 reached 4,222, accounting for 51.6 per cent in the market. The total number of reported medical devices, including imports, reached 8,183, slightly down from 8,269 in 2019. The COVID-19 pandemic was a major factor contributing to the increase in locally produced devices.
In 2020, around 249 COVID-19 test kits received production and export approvals, accounting for 22 per cent of all medical devices with manufacturing approvals.
A sudden surge in Artificial Intelligence (AI)- powered medical devices was witnessed in 2020 with around 50 devices being approved compared to only 10 devices in 2019. Out of which, 45 were developed by local companies, and five were imported, mostly under the category of AI-based telemedicine software.
Trends and drivers
Post pandemic, the South Korean government is sensing a strong business opportunity to boost the economy which suffered during the pandemic. With an increase in overseas demand for Korean-made medical devices, domestic manufacturers are targeting the international market with competitive prices and services. After successfully containing COVID-19 with mostly domestically produced aids, the country is keen on boosting the competitiveness of the regional medtech sector by emphasis on manufacture of futuristic medical tools.
According to the Ministry of Economy and Finance, the country’s biohealth exports have shown a high annual growth of about 40 to 50 per cent since the pandemic. The number of pharmaceutical and biotech companies with sales exceeding 1 trillion won ($868 million) also doubled from six in 2018 to 12 in 2020.
Esta historia es de la edición BioSpectrum Asia Sep 2021 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
"The next 5-years will see mRNA science evolve beyond infectious disease"
A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
No Funding No Vax for TB?
The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Australia builds tailored heart pump to transform heart failure care
Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles
APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia
Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026
In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.
1 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Fujifilm launches joint research with National Cancer Center in Japan
Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics
Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Submitting clinical data to the FDA and PDMA: An efficient and compliant approach
In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches
After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:
7 mins
BioSpectrum Asia Dec 2025
Translate
Change font size

